Eesti - eesti - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 12mcg+200mcg 1annus 60annus 3tk; 12mcg+200mcg 1annus 60annus 1tk; 12mcg+200mcg 1annus 60annus 2tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - formoterool+budesoniid - annustatud inhalatsioonipulber - 9mcg+320mcg 1mõõtannus 60mõõtannus 3tk; 9mcg+320mcg 1mõõtannus 60mõõtannus 6tk; 9mcg+320mcg 1mõõtannus 60mõõtannus 2tk

Eesti - eesti - Ravimiamet

portfarma ehf. - raloksifeen - õhukese polümeerikattega tablett - 60mg 90tk; 60mg 30tk; 60mg 14tk; 60mg 84tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol dietüülfumaraat dihüdraat, glycopyrronium bromiid - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - ravimid hingamisteede obstruktiivsete haiguste, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Eesti - eesti - Ravimiamet

olainfarm as - nitrofurantoiin - toimeainet modifitseeritult vabastav kõvakapsel - 100mg 14tk

Eesti - eesti - Ravimiamet

portfarma ehf. - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 37,5mg 28tk; 37,5mg 100tk

Eesti - eesti - Ravimiamet

portfarma ehf. - esomeprasool - gastroresistentne tablett - 40mg 14tk; 40mg 7tk; 40mg 56tk; 40mg 98tk; 40mg 30tk; 40mg 90tk; 40mg 100tk

Eesti - eesti - Ravimiamet

jsc olainfarm - pürasiinamiid - tablett - 500mg 1000tk